Aktienanalyse zu LivaNova PLC (LIVN)LIVNLivaNova PLC

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

LivaNova PLC (LIVN) is a good buy right now due to its strong recent performance, including a 32.45% year-to-date change and a record Q2 2026 revenue of $391 million, which surpassed analyst expectations. The current price of $80.32 is below the average analyst price target of $88.75, indicating potential upside. The RSI is at 56.54, suggesting the stock is neither overbought nor oversold, which is favorable for entry. However, the main risk is the recent drop of 8.41% following the last earnings report, which could indicate volatility in the short term.

9 analysts cover LIVN: 5 rate it Buy, 3 Hold and 1 Sell. The average price target is 72.50.